0201 Gritstone Gilead
BioCentury & Getty Images


Gritstone seeks value in infectious diseases through Gilead deal, but isn’t leaving neoantigens behind

Feb 2, 2021 | 2:30 AM GMT

While neoantigen cancer vaccines have yet to meet high investor expectations, Gritstone is uncovering new value for its neoantigen platform in infectious diseases, most recently through a partnership with Gilead to develop HIV vaccines. 

On Monday, Gritstone Oncology Inc. (NASDAQ:GRTS) and Gilead Sciences Inc. (NASDAQ:GILD) announced a new collaboration to develop curative HIV vaccines by combining Gritstone’s vaccine platform with Gilead’s

Read the full 859 word article

How to gain access

Continue reading with a
two-week free trial.